HIPEC Surgery: Indications, Patient Selection, and Perioperative Considerations
For colorectal peritoneal metastases, cytoreductive surgery (CRS) alone should be performed at specialized high-volume centers, but the addition of HIPEC is NOT recommended based on the most recent high-quality evidence showing no survival benefit and increased complications. 1
Disease-Specific Indications
Colorectal Peritoneal Metastases
The PRODIGE 7 trial (2023) fundamentally changed practice for colorectal cancer. CRS may be offered to highly selected patients with isolated colorectal peritoneal metastases, but adding HIPEC provides no benefit 1. This phase III RCT of 256 patients demonstrated:
- No difference in overall survival (HR 1.00; 95% CI 0.63-1.58)
- No difference in recurrence-free survival (HR 0.91; 95% CI 0.71-1.15)
- Significantly more grade 3+ adverse events at 60 days with HIPEC (RR 1.69; 95% CI 1.03-2.77) 1
- 15% of patients remained disease-free at 5 years with CRS alone, indicating potential for cure in appropriately selected patients 1
The earlier Verwaal trial showed survival benefit for CRS+HIPEC versus chemotherapy alone (HR 0.55), but had 8% treatment-related mortality and couldn't separate the benefit of aggressive cytoreduction from HIPEC itself 1.
Ovarian Cancer
For stage III tubo-ovarian carcinoma, HIPEC at interval cytoreductive surgery showed improved survival in one prospective trial, but no consensus exists among experts 2. The 2024 ESGO-ESMO-ESP guidelines note considerable ongoing debate, with only 85.4% consensus reached—reflecting genuine equipoise in the field 2.
Other Indications
CRS-HIPEC is performed for:
- Appendiceal malignancies (most common indication, 64% of cases) 3
- Pseudomyxoma peritonei
- Peritoneal mesothelioma
- Selected gastric cancer cases
Critical Patient Selection Criteria
Mandatory Requirements
Patients must meet ALL of the following 1, 4:
Limited peritoneal disease burden: Peritoneal Cancer Index (PCI) ideally <10 for minimally invasive approaches 5; median PCI of 13 in contemporary series 3
Achievable complete cytoreduction: This is the single most important prognostic factor. After complete resection (CCR-0), only 1 of 18 patients died at median 21.6-month follow-up, versus 66-70% mortality with residual disease 1
No distant metastases (for colorectal): Isolated peritoneal disease only. Presence of liver metastases carries negative prognosis 4
Adequate performance status: Must tolerate major surgery with potential multi-visceral resections
Treatment at specialized high-volume center (>10 cases/year): Outcomes are highly center-dependent 1
Negative Prognostic Factors to Consider
- Signet ring cell histology: Strong negative predictor 4
- Absence of neoadjuvant systemic therapy: Associated with worse outcomes 4
- Extensive disease on structured radiology: May warrant diagnostic laparoscopy first 2
Prognostic Tools
The Colorectal Peritoneal Metastases Prognostic Surgical Score (COMPASS) nomogram combines multiple factors to guide selection, though no universally accepted scoring system exists 2, 4.
Perioperative Management Framework
Preoperative Preparation
68% of high-volume centers use formal preparatory pathways, but only 26% have implemented enhanced recovery protocols 6. Key elements include:
- Multidisciplinary team evaluation (mandatory): Must include surgical oncology, medical oncology, radiology, pathology 1
- Structured imaging assessment: To evaluate disease extent and predict resectability 2
- Consider diagnostic laparoscopy: When concern exists for incomplete cytoreduction based on imaging 2
- Neoadjuvant systemic therapy: Should be considered; absence associated with worse outcomes 4
Intraoperative Considerations
- Complete cytoreduction is paramount: Residual disease <1mm required for any potential benefit 1
- Multi-visceral resections often necessary: To achieve complete cytoreduction 7
- Intraoperative technical practices relatively standardized across centers 6
- Minimally invasive approach feasible in highly selected patients with PCI <10 and favorable histologies (pseudomyxoma, mesothelioma, ovarian) 5
Postoperative Management
Morbidity remains high (55-57%) despite improvements 3. The 2020 ERAS Society guidelines provide 71 evidence-based recommendations for CRS±HIPEC 7:
- Expected complications: Grade 3-5 adverse events occur in ~65% of patients; surgical complications requiring reintervention in 35% 1
- Treatment-related mortality: 3-8% depending on disease extent and patient selection 1, 3
- Length of stay: Median 4-13 days, trending shorter over time 5, 3
- Blood loss and transfusion needs: Decreasing with experience but remain significant 3
Critical gap: Wide variation exists in postoperative care practices including analgesia methods, timing of ambulation, DVT prophylaxis, and antibiotic duration 6. Enhanced recovery protocols are underutilized despite potential benefits 7, 6.
Shared Decision-Making Requirements
Mandatory discussion points with patients 1:
- High morbidity rate (55-65%)
- Mortality risk (3-8%)
- Significant impact on quality of life
- For colorectal disease: HIPEC adds toxicity without survival benefit
- Alternative: systemic chemotherapy alone may be appropriate
- Requirement for treatment at specialized center
Key Clinical Pitfalls
Adding HIPEC to CRS for colorectal peritoneal metastases: The PRODIGE 7 trial definitively shows no benefit with increased harm 1
Attempting CRS when complete cytoreduction unlikely: Incomplete cytoreduction (residual disease >1mm) eliminates any potential benefit 1, 4
Operating at low-volume centers: Outcomes are highly volume-dependent; this procedure should only be performed at specialized centers 1
Inadequate preoperative assessment: Structured imaging and potential diagnostic laparoscopy prevent futile laparotomies 2
Ignoring negative prognostic factors: Signet ring histology, liver metastases, and high PCI predict poor outcomes 4